Eczane Pharma Private Limited

Founded in 2021 and headquartered in Bihar, India.

2021 | Patna, Bihar (India) | Active
Last Updated: December 26, 2024

Eczane Pharma Profile

Key Indicators

  • Authorised Capital ₹ 1.00 M
  • Paid Up Capital ₹ 0.10 M
  • Company Age 3 Year, 2 Months
  • Last Filing with ROC 31 Mar 2024

About Eczane Pharma

Eczane Pharma Private Limited (EPPL) is a Private Limited Indian Non-Government Company incorporated in India on 16 November 2021 (Three years and two months 30 days old ). Its registered office is in Patna, Bihar, India.

The Company is engaged in the Chemicals Industry.

The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.

Abu Saleh and Md Khan serve as directors at the Company.

Company Details

  • Location

    Patna, Bihar, India

  • Telephone

    +91-XXXXXXXXXX

  • Email Address

  • Website

    -

  • Social Media
    -

Corporate Identity Details

  • CIN/LLPIN

    U24290BR2021PTC055148

  • Company No.

    055148

  • Company Classification

    Private Limited Indian Non-Government Company

  • Incorporation Date

    16 Nov 2021

  • Date of AGM

    28 Sep 2024

  • Date of Balance Sheet

    31 Mar 2024

  • Listing Status

    Unlisted

  • ROC Code

    Roc Patna

Industry

Chemicals

Who are the key members and board of directors at Eczane Pharma?

Board Members (2)

Name Designation Appointment Date Status
Abu Saleh Country flag representing In Director 16-Nov-2021 Current
Md Khan Country flag representing In Director 16-Nov-2021 Current

Financial Performance of Eczane Pharma.

Enhance accessibility to Eczane Pharma's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.

Graph illustrating revenue growth over time
Graph showing profit and loss trends over time
  • Key Matrics
  • Balance Sheet
  • Profit and Loss
  • Cash Flow
  • Ratios
Metrics
(FY 2023) YOY Growth
(FY 2022) (FY 2021) (FY 2020) (FY 2019)
Total Revenue
Revenue from Operations
Total Assets
Profit or Loss
Net Worth
EBITDA

What is the Ownership and Shareholding Structure of Eczane Pharma?

Unlock access to Eczane Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.

Shareholding Indicator graph

Charges (Loans)

Placeholder for charges-related data

There are no open charges registered against the company as per our records.

How Many Employees Work at Eczane Pharma?

Eczane Pharma has a workforce of 0 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.

Graph showing employee growth trends

Deals i

Graph showing company valuation over time

Gain comprehensive insights into the Deals and Valuation data of Eczane Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Eczane Pharma's trajectory.

Rating

Graph displaying rating trends over time

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.

Alerts

Alert Indicator

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.

Latest Updates, News, and FAQs on Eczane Pharma

Recent activity within the organization

  • Annual General Meeting

    Eczane Pharma Private Limited last Annual general meeting of members was held on 28 Sep 2024 as per latest MCA records.

    28 Sep 2024

  • Balance Sheet

    Eczane Pharma Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Patna.

    31 Mar 2024

  • Director Appointment

    Abu Saleh was appointed as a Director was appointed as a Director on 16 Nov 2021 & has been associated with this company since 3 years 2 months .

    16 Nov 2021

  • Director Appointment

    Md Iliyas Khan was appointed as a Director was appointed as a Director on 16 Nov 2021 & has been associated with this company since 3 years 2 months .

    16 Nov 2021

  • Company Incorporation

    Eczane Pharma Private Limited was registered on 16 Nov 2021 with Roc Patna & aged 3 years 2 months as per MCA records.

    16 Nov 2021

Frequently asked questions

  • Eczane Pharma Private Limited was incorporated on 16 Nov 2021.

  • The authorized share capital of Eczane Pharma Private Limited is ₹ 1.00 M and paid-up capital is ₹ 0.10 M.

  • Currently 2 directors are associated with Eczane Pharma Private Limited.

    • Abu Saleh
    • Md Iliyas Khan
  • As per Ministry of Corporate Affairs (Mca), the registered address of Eczane Pharma Private Limited is C/O Shafiur Rahman S/O H.M. Jaan Phulwari Sharif, Naya Tola India, Patna, Bihar, 801505.

  • The corporate identification number (CIN) of Eczane Pharma Private Limited is U24290BR2021PTC055148 and the company number is 055148 as per Ministry of Corporate Affairs (MCA).

  • The most recent Balance Sheet for Eczane Pharma Private Limited was filed with the ROC on 31 Mar 2024.